TI
GPCR icon

TrueMark Investments’s Structure Therapeutics GPCR Stock Holding History

TrueMark Investments’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Buy
34,377
+484
+1% +$33.1K 0.32% 68
2025
Q4 		$2.36M Sell
33,893
-968
-3% -$39.5K 0.45% 63
2025
Q3 		$976K Sell
34,861
-2,904
-8% -$57.8K 0.17% 126
2025
Q2 		$783K Sell
37,765
-1,452
-4% -$31.9K 0.17% 123
2025
Q1 		$679K Sell
39,217
-2,910
-7% -$71.3K 0.18% 105
2024
Q4 		$1.14M Sell
42,127
-3,353
-7% -$119K 0.36% 85
2024
Q3 		$2M Buy
45,480
+15,596
+52% +$603K 0.64% 59
2024
Q2 		$1.17M Hold
29,884
– – 0.4% 87
2024
Q1 		$1.28M Buy
29,884
+3,562
+14% +$150K 1.18% 39
2023
Q4 		$1.07M Buy
+26,322
New +$1.51M 1.07% 47

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

TrueMark Investments's GPCR Position: Q1 2026 in Review

TrueMark Investments increased its Structure Therapeutics (GPCR) stake by 1.4% in Q1 2026, buying an estimated $33.1K and bringing the position to 34,377 shares worth $1.66M. The position accounts for 0.32% of the portfolio, ranked #68.

TrueMark Investments first reported a position in GPCR in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.36M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • TrueMark Investments held 34,377 shares of Structure Therapeutics worth $1.66M as of Q1 2026.
  • TrueMark Investments bought 484 Structure Therapeutics shares in Q1 2026, an estimated $33.1K.
  • Structure Therapeutics made up 0.32% of TrueMark Investments's portfolio in Q1 2026, its #68 holding.
  • TrueMark Investments first reported a position in Structure Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • TrueMark Investments's Structure Therapeutics position peaked at $2.36M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on TrueMark Investments's 13F filing for Q1 2026, filed 20 Apr 2026.